Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

Nov 13, 2018

Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

Nov 12, 2018

Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma

Oct 2, 2018

Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Sep 27, 2018

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

Sep 25, 2018

Cellectar Biosciences Provides an Update on the FDA Import Alert

Sep 24, 2018

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

Sep 17, 2018

Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Aug 29, 2018

Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients

Aug 20, 2018

Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma

Aug 13, 2018